Takara Bio Establishes Foothold in the Pluripotent Stem Cell Market

Takara Bio broke news that the Medical Products Agency (“MPA”) granted the company a manufacturing license for derivation and banking of human embryonic stem (hES) cells to be produced under GMP conditions. The cells will be produced at Takara Bio’s manufacturing laboratory in Göteborg, Sweden. Takara Bio is the first company worldwide to offer this service for human ESCs.

Improved T cell culture and preservation of naïve phenotype through novel media supplementation

The demands of cell therapy production have led to an increasing need for novel cell culture media. University of Pennsylvania’s Dr. Roddy O’Connor presented a poster at the Cancer Immunotherapy Conference last week showing the use of serum replacement, Physiologix ™ XF hGFC, in T cell production. The poster addresses growing concerns about phenotype maintenance, transduction efficiency and consistency - and how new media alternatives can be used to enhance CAR-T cells. Download it here.

Gradalis® implements L7 Informatics’ Enterprise Science Platform as part of initiating their Phase 3 Study of Vigil™ in Ewing’s sarcoma

DALLAS, October 3, 2018 – Gradalis, Inc., a Dallas-based, clinical-stage, vertically-integrated immunotherapy company, announced it has successfully implemented and launched L7’s Enterprise Science Platform (“ESP”). L7 Informatics, Inc., is the leading software and analytics company for life science research and manufacturing companies.

UniCAR Therapy and Terumo BCT Collaborate to Advance CAR T-Cell Therapies and Create a Shanghai, China Center of Excellence

LAKEWOOD, Colo., Oct. 09, 2018 — Shanghai UniCAR-Therapy Bio-Medicine Technology Co. chose Terumo BCT and its cell expansion devices to automate its cell therapy manufacturing process for chimeric antigen receptor (CAR) T-cell therapies. Privately held, UniCAR will open their Center of Excellence for Terumo BCT’s technologies in Shanghai in November.

CHAMP Private Equity Acquires Cell Care, Australia’s Largest Cord Blood Bank

CHAMP Private Equity is acquiring Cell Care, the largest cord blood bank in Australia. According to the Australian Financial Review, the price tag of deal is greater than a $100 million. Previously in 2016, Cell Care acquired Insception Lifebank, the largest cord blood bank in Canada. The transaction continues the global trend of cord blood industry consolidation.

When Did Cord Blood Banking Start? Landmark Events in Cord Blood & Tissue

The global cord blood industry came into existence in the early 1990’s with the formation of several leading cord blood banks in the USA, followed by the establishment of cord blood banks across the globe. Today, market events are happening at an ever accelerating pace.

L7 Informatics Releases L7 Enterprise Science Platform 2.0 with Pre-Built Microsoft Genomics Integration

AUSTIN, Texas, Oct. 10, 2018 — L7 Informatics, Inc., formerly Lab7 Systems, a leader in informatics solutions and services for data intensive scientific applications and personalized medicine, is pleased to announce the release of Enterprise Science Platform 2.0 (ESP) with a validated pre-built Microsoft Azure connector to the Microsoft Genomics service on the Azure cloud.

What Is Carpal Tunnel | Everything You Need To Know

With those first few wrist twinges, you may start to research what is carpal tunnel and what it isn’t. As the condition progresses, carpal tunnel syndrome symptoms become unmistakable. Many people worry that surgery is their only hope to ease this chronic problem. However, other carpal tunnel syndrome therapy options exist.

Companies Developing Stem Cell Therapeutics

Stem cell companies have been rapidly populating on a global basis, reaching nearly 100 market competitors that are developing stem cell therapeutics for use in humans. Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into mature cell types.

(My Story) President of a Stem Cell Market Research Firm and a Stem Cell Patient

For the past 15 years, I have studied stem cells. I have been fascinated with them for most of my adult life, founding BioInformant as the first and only market research firm to specialize in the stem cell industry. However, it was only recently that I experienced the power of stem cells to impact my own life and health.

Defining the Future of the Stem Cell Industry [Interview Package]

Using our unrivaled access to stem cell industry executives, this 374-page report features interviews with 54 leading stem cell executives worldwide, giving you an inside look into the future of the stem cell industry from the people who are creating it. For the next 48 hours, you can claim it for 60% off (only $197). 

Regenerative Medicine Industry Database – Featuring 650+ Companies Worldwide

To characterize the rapidly growing Regenerative Medicine (RM) Industry, this database features 650+ companies worldwide that are developing these products for therapeutic use in humans. It was originally developed in-house for our own purposes, but we have had more and more readers requesting access to it. For a limited-time, you can access this searchable, sortable database of 650+ regenerative medicine companies for only $97 (50% off).

SHOP     STEM CELLS     CORD BLOOD     EXOSOMES     CELL THERAPY